HAS2 and pancreatic neoplasm: The results revealed that pancreatic cancer patients with high expression of SPHK1 had shorter OS than patients with low SPHK1 expression (P = 0.037) (Figure 4(a)), and pancreatic cancer patients with high HAS2 expression had shorter OS than patients with low expression of HAS2 (P = 0.0074) (Figure 4(b)).